Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chrysotherapy-induced aplastic anemia: a case report.

C A Shearer, W A Parker

    American Journal of Hospital Pharmacy
    |September 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Increase of Lunacy.

    Glasgow medical journal·2018
    Same author

    Canadian Drug Products Containing ASA.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    A reassessment of two freshwater ascomycetes, Ceriospora caudae-suis and Submersisphaeria aquatica.

    Mycologia·2010
    Same author

    Systematics of Halosarpheia based on morphological and molecular data.

    Mycologia·2010
    Same author

    Clinical pharmacology of sodium salicylate.

    The Quarterly journal of medicine·2010
    Same author

    A class-wide phylogenetic assessment of Dothideomycetes.

    Studies in mycology·2010

    Gold sodium thiomalate can cause fatal aplastic anemia in rheumatoid arthritis patients. Close monitoring and dose adjustment are crucial for preventing this severe hematologic side effect.

    Area of Science:

    • Hematology
    • Rheumatology
    • Clinical Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic inflammatory disorder.
    • Chrysotherapy, using gold salts like gold sodium thiomalate, has been a treatment for RA.
    • Hematologic side effects, including aplastic anemia, are known risks of gold therapy.

    Observation:

    • A case report details a 58-year-old male with RA who developed aplastic anemia.
    • The patient received a cumulative dose of 635 mg of gold sodium thiomalate over 16 weeks.
    • This highlights a severe adverse reaction to gold treatment.

    Findings:

    • Gold-induced aplastic anemia is a potentially fatal hematologic complication.
    • Predicting individual patient risk for this side effect remains challenging.

    Related Experiment Videos

  • Current understanding does not allow for absolute identification of at-risk individuals.

    • Implications:

    • While chrysotherapy offers RA treatment benefits, the risk of aplastic anemia necessitates caution.
    • Dosage reduction and rigorous monitoring of clinical and laboratory signs are vital for prevention.
    • Further research may improve risk stratification for gold-induced hematologic toxicity.